Novartis announced plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing facility in Denton, Texas, the company’s first such site in the state and fifth in the U.S., to expand its ability to produce targeted cancer therapies as demand grows. The facility, expected to begin operations in 2028, is part of Novartis’ broader $23 billion investment in U.S. manufacturing and will create jobs in bioengineering, advanced manufacturing, quality, and operations while supporting timely delivery of life-saving treatments.
